Exposure to aripiprazole during embryogenesis: A prospective multicenter cohort study

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 4, 2015, Pages 368-380

  Bellet, Florelle ^a   Beyens, Marie Noëlle ^a   Bernard, Nathalie ^b   Beghin, Delphine ^c   Elefant, Elisabeth ^c   Vial, Thierry ^b  

^a Centre Hospitalo Universitaire   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Aripiprazole; Cohort study; Embryogenesis; Malformation; Pharmacoepidemiology; Pregnancy

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ASPIRATION PNEUMONIA; BIPOLAR DISORDER; CARDIOVASCULAR MALFORMATION; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; DEPRESSION; DRUG SURVEILLANCE PROGRAM; EMBRYO DEVELOPMENT; ENVIRONMENTAL EXPOSURE; ESOPHAGUS ATRESIA; FEMALE; FETOTOXICITY; FETUS; FOLLOW UP; GESTATIONAL AGE; HUMAN; HYDRAMNIOS; INTRAUTERINE GROWTH RETARDATION; LIVE BIRTH; MAJOR CLINICAL STUDY; MATERNAL AGE; NEWBORN; OBSERVATIONAL STUDY; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; SCHIZOPHRENIA; SPONTANEOUS ABORTION; THERAPEUTIC ABORTION; TREATMENT DURATION; TREATMENT INDICATION; WITHDRAWAL SYNDROME; ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADVERSE EFFECTS; CHEMICALLY INDUCED; CLINICAL TRIAL; MATERNAL EXPOSURE; MIDDLE AGED; MULTICENTER STUDY; PREGNANCY; PREGNANCY COMPLICATION;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; COHORT STUDIES; FEMALE; FETAL GROWTH RETARDATION; HUMANS; MATERNAL EXPOSURE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; PROSPECTIVE STUDIES;

EID: 84925945090     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3749     Document Type: Article

References (33)

1. Reprotox. Aripiprazole, 2013. Available at: http://www.reprotox.org (accessed October 2013).
2. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk (7th edn). Philadelphia: Lippincott Williams & Wilkins, 2005; 97-98.
3. Wichman CL. Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health 2009; 12(1): 53-57.
4. Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol 2013; 33(4): 453-462. doi:10.1097/JCP.0b013e318295fe12.
5. Paulus WE. Is the use of aripiprazole safe during first trimester of pregnancy? [abstract]. Reprod Toxicol 2013; 37: 87.
6. Kulkarni J, Worsley R, Gilbert H, et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One 2014; 9(5): e94788.
7. Mendhekar DN, Sunder KR, Andrade C. Aripiprazole use in a pregnant schizoaffective woman. Bipolar Disord 2006; 8(3): 299-300.
8. Doulgeraki G, Karadima D, Kalogiratos G, et al. Pregnancy, aripiprazole and psychotherapy [abstract]. Eur Psychiatry 2007; 22: S206.
9. Mervak B, Collins J, Valenstein M. Case report of aripiprazole usage during pregnancy. Arch Womens Ment Health 2008; 11(3): 249-250. doi:10.1007/s00737-008-0022-9.
10. Lutz UC, Hiemke C, Wiatr G, et al. Aripiprazole in pregnancy and lactation: a case report. J Clin Psychopharmacol 2010; 30(2): 204-205. doi:10.1097/JCP.0b013e3181d27c7d.
11. Nguyen T, Teoh S, Hackett LP, et al. Placental transfer of aripiprazole. Aust N Z J Psychiatry 2011; 45(6): 500-501. doi:10.3109/00048674.2011.566547.
12. Widschwendter CG, Hofer A. Aripiprazole use in early pregnancy: a case report. Pharmacopsychiatry 2012; 45(7): 299-300. doi:10.1055/s-0032-1312591.
13. Derganc M, Savs AP. The use of aripiprazole during pregnancy: a case report [abstract]. Eur Psychiatry 2013; 28: S1.
14. Nordeng H, Gjerdalen G, Brede WR, et al. Transfer of aripiprazole to breast milk: a case report. J Clin Psychopharmacol 2014; 34(2): 272-275.
15. Windhager E, Kim SW, Saria A, et al. Perinatal use of aripiprazole: plasma levels, placental transfer, and child outcome in 3 new cases. J Clin Psychopharmacol 2014; 34(5): 637-641. doi:10.1097/JCP.0000000000000171.
16. Mendhekar DN, Sharma JB, Srilakshmi P. Use of aripiprazole during late pregnancy in a woman with psychotic illness. Ann Pharmacother 2006; 40(3): 575.
17. Watanabe N, Kasahara M, Sugibayashi R, et al. Perinatal use of aripiprazole: a case report. J Clin Psychopharmacol 2011; 31(3): 377-379. doi:10.1097/JCP.0b013e318218c400.
18. Gentile S, Tofani S, Bellantuono C. Aripiprazole and pregnancy: a case report and literature review. J Clin Psychopharmacol 2011; 31(4): 531-532. doi:10.1097/JCP.0b013e318222bc65.
19. Rasmussen SA, Olney RS, Holmes LB, et al. Guidelines for case classification for the national birth defects prevention study. Birth Defects Res A Clin Mol Teratol 2003; 67(3): 193-201.
20. EUROCAT. Minor anomalies for exclusion, 2005. Available at: http://www.eurocat-network.eu/content/EUROCAT-New-List-of-Minor-Anomalies.pdf (accessed July 2012).
21. AUDIPOG. Estimation de la croissance fœtale et postnatale. Available at: http://www.audipog.net/courbes_morpho.php (accessed August 2012).
22. Matevosyan NR. Pregnancy and postpartum specifics in women with schizophrenia: a meta-study. Arch Gynecol Obstet 2011; 283(2): 141-147.
23. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339: b3569. doi:10.1136/bmj.b3569.
24. Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008; 83: 68-76.
25. Reis M, Källén B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open 2013; 3(2). doi:10.1136/bmjopen-2012-002166.
26. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005; 66(4): 444-449.
27. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. Br Med J 1997; 315(7099): 32-34.
28. Blondel B, Lelong N, Kermarrec M, et al. Trends in perinatal health in France between 1995 and 2010: results from the National Perinatal Surveys. J Gynecol Obstet Biol Reprod 2012; 41(2): 151-166. doi:10.1016/j.jgyn.2011.11.008.
29. Savitz DA, Murnane P. Behavioral influences on preterm birth: a review. Epidemiology 2010; 21(3): 291-299. doi:10.1097/EDE.0b013e3181d3ca63.
30. Matsubara F, Kida M, Tamakoshi A, et al. Maternal active and passive smoking and fetal growth: a prospective study in Nagoya, Japan. J Epidemiol 2000; 10(5): 335-343.
31. FDA Drug Safety Communication. Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm (accessed October 2013).
32. Ulcickas Yood M, Delorenze GN, Quesenberry CP, Jr, et al. Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? BMC Psychiatry 2011; 11: 197.
33. Ko YK, Soh MA, Kang SH, et al. The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics. Clin Psychopharmacol Neurosci 2013; 11(2): 80-88. doi:10.9758/cpn.2013.11.2.80.